Objective To investigate the nature and extent of financial relationships between leaders of influential professional medical associations in the United States and pharmaceutical and device companies. Design Cross sectional study. Setting Professional associations for the 10 costliest disease areas in the US according to the US Agency for Healthcare Research and Quality. Financial data for association leadership, 2017-19, were obtained from the Open Payments database. Population 328 leaders, such as board members, of 10 professional medical associations: American College of Cardiology, Orthopaedic Trauma Association, American Psychiatric Association, Endocrine Society, American College of Rheumatology, American Society of Clinical Oncology, American Thoracic Society, North American Spine Society, Infectious Diseases Society of America, and American College of Physicians. Main outcome measures Proportion of leaders with financial ties to industry in the year of leadership, the four years before and the year after board membership, and the nature and extent of these financial relationships. Results 235 of 328 leaders (72%) had financial ties to industry. Among 293 leaders who were medical doctors or doctors of osteopathy, 235 (80%) had ties. Total payments for 2017-19 leadership were almost $130m (£103m; €119m), with a median amount for each leader of $31 805 (interquartile range $1157 to $254 272). General payments, including those for consultancy and hospitality, were $24.8m and research payments were $104.6m—predominantly payments to academic institutions with association leaders named as principle investigators. Variation was great among the associations: median amounts varied from $212 for the American Psychiatric Association leaders to $518 000 for the American Society of Clinical Oncology. Conclusions Financial relationships between the leaders of influential US professional medical associations and industry are extensive, although with variation among the associations. The quantum of payments raises questions about independence and integrity, adding weight to calls for policy reform.

中文翻译：

---

有影响力的美国专业医学协会领导人与行业之间的财务联系：横断面研究。

目的 调查美国有影响力的专业医学协会领导人与制药和设备公司之间财务关系的性质和程度。设计横断面研究。根据美国医疗保健研究和质量局的数据，为美国 10 个成本最高的疾病领域设立专业协会。2017-19 年协会领导层的财务数据来自开放支付数据库。10个专业医学协会的328名领导者，如董事会成员：美国心脏病学会、骨科创伤协会、美国精神病学协会、内分泌学会、美国风湿病学会、美国临床肿瘤学会、美国胸科学会、北美脊柱学会、美国传染病学会和美国医师学会。主要成果衡量领导当年、担任董事会成员的前四年和后一年与行业有财务联系的领导人的比例，以及这些财务关系的性质和程度。结果 328 名领导者中有 235 名 (72%) 与工业有财务联系。在 293 名担任医生或整骨医生的领导人中，有 235 名（80%）有关系。2017-19 年领导层的薪酬总额接近 1.3 亿美元（1.03 亿英镑；1.19 亿欧元），每位领导层的中位数金额为 31 805 美元（四分位数范围为 1157 美元至 254 272 美元）。一般付款（包括咨询和招待费用）为 2,480 万美元，研究付款为 1.046 亿美元——主要支付给由协会领导人担任主要研究人员的学术机构。各个协会之间的差异很大：中位金额从美国精神病学协会领导人的 212 美元到美国临床肿瘤学会的 518 000 美元不等。结论 美国有影响力的专业医学协会领导者与行业之间的财务关系广泛，尽管协会之间存在差异。支付数额引发了对独立性和完整性的质疑，增加了政策改革的呼声。